NEW YORK, Jan. 18, 2023 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2022 financial results on Wednesday, February 15, 2023 before the US stock markets open. The Company will hold a conference call and webcast simultaneously at 8:00 a.m. Eastern Time that day.
Conference Call Information
Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/news-and-events/events for conference call information and to view the live webcast. Replays of the conference call and webcast will be archived on the company’s website for at least 30 days.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalty funds and a leading sponsor of innovation across the biopharmaceutical industry, partnering with innovators from academia, research hospitals and nonprofits through small and medium-sized companies biotechnology leading global pharmaceutical companies. . Royalty Pharma has put together a portfolio of royalties that give it the right to make payments based directly on the sales of many of the industry’s leading therapies. Royalty Pharma supports innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to fund late-stage clinical trials and new product launches in exchange for future benefits, and indirectly when it receives existing benefits from early innovators. Royalty Pharma’s current portfolio includes the benefits of more than 35 commercial products, including Vertex’s Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri, AbbVie and Johnson & Johnson’s Imbruvica Johnson, Astellas and Pfizer’s Xtandi, GSK’s Trelegys, Novarte’s, Novarte’s, Novarte’s, Novarte’s Promac OD, Novarte’s Johnson’s Johnson’s Tremfya, Evrysdi’s Roche, Gilead’s Trodelvy, and 12 development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6772